Page 24 - GALENIKA MEDICAL JOURNAL

11. Mercuro NJ, Veve MP. Clinical Utility of Lefamulin: If Not Now, When? Urinary Tract Infections. Antimicrob Agents Chemother. 2022 May
Curr Infect Dis Rep. 2020;22(9):25. 17;66(5):e0239621.
12. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, 31. Zhao CY, Lv Y, Zhu Y, Wei MJ, Liu MY, Ji XW, et al. A First-in-Human
et al. Cefiderocol: A Siderophore Cephalosporin with Activity Against Safety, Tolerability, and Pharmacokinetics Study of Benapenem in
Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Healthy Chinese Volunteers. Antimicrob Agents Chemother. 2019 Feb
Drugs. 2019 Feb;79(3):271-89. 26;63(3):e02188-18.
13. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. 32. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, et al.
Efficacy and safety of cefiderocol or best available therapy for the Analysis of the Clinical Pipeline of Treatments for Drug-Resistant
treatment of serious infections caused by carbapenem-resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121.
multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect
Dis. 2021 Feb;21(2):226-40. 33. Di Bonaventura G, Lupetti V, Verginelli F, Giancristofaro S, Barbieri R,
Gherardi G, et al. Repurposing the Veterinary Antibiotic Apramycin for
14. Mansour H, Ouweini AEL, Chahine EB, Karaoui LR. Imipenem/cilastatin/ Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa
relebactam: A new carbapenem β-lactamase inhibitor combination. Am From Cystic Fibrosis Patients. Front Microbiol. 2022 Feb 3;12:801152.
J Health Syst Pharm. 2021 Mar 31;78(8):674-83.
34. Gysin M, Hon PY, Tan P, Sengduangphachanh A, Simmalavong M,
15. Clark JA, Burgess DS. Plazomicin: a new aminoglycoside in the fight Hinfonthong P, et al. Apramycin susceptibility of multidrug-resistant
against antimicrobial resistance. Ther Adv Infect Dis. 2020 Sep Gram-negative blood culture isolates in five countries in Southeast Asia.
4;7:2049936120952604. Int J Antimicrob Agents. 2022 Oct;60(4):106659.
16. Patel TS, Pogue JM, Mills JP, Kaye KS. Meropenem-vaborbactam: a new 35. Domalaon R, De Silva PM, Kumar A, Zhanel GG, Schweizer F. The
weapon in the war against infections due to resistant Gram-negative Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses
bacteria. Future Microbiol. 2018 Jul;13(9):971-83. Colistin Resistance in Gram-Negative Bacilli. Antimicrob Agents
Chemother. 2019 Mar 27;63(4):e02574-18.
17. Scott LJ. Eravacycline: A Review in Complicated Intra-Abdominal
Infections. Drugs. 2019 Feb;79(3):315-24. 36. Miller RD, Iinishi A, Modaresi SM, Yoo BK, Curtis TD, Lariviere PJ, et al.
Computational identification of a systemic antibiotic for gram-negative
18. Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, et bacteria. Nat Microbiol. 2022 Oct;7(10):1661-72.
al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline
Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313. 37. Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman
N, Tiffany C, et al. Design of Two Phase III, Randomized, Multicenter
19. Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The Revival Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment
of Aztreonam in Combination with Avibactam against Metallo-β- of Uncomplicated Urinary Tract Infection in Female Participants. Infect
Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Dis Ther. 2022 Dec;11(6):2297-310.
Studies and Clinical Cases. Antibiotics (Basel). 2021 Aug 20;10(8):1012.
38. Ifrid E, Ouertatani-Sakouhi H, Jauslin T, Kicka S, Chiriano G, Harrison CF,
20. Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Castanheira M. et al. 5-ethyl-2'-deoxyuridine fragilizes Klebsiella pneumoniae outer wall
Antimicrobial activities of aztreonam-avibactam and comparator agents and facilitates intracellular killing by phagocytic cells. PLoS One. 2022
tested against Enterobacterales from European hospitals analysed by Oct 31;17(10):e0269093.
geographic region and infection type (2019-2020). Eur J Clin Microbiol
Infect Dis. 2022 Mar;41(3):477-87. 39. Zhu M, Tse MW, Weller J, Chen J, Blainey PC. The future of antibiotics
begins with discovering new combinations. Ann N Y Acad Sci. 2021
21. Nordmann P, Yao Y, Falgenhauer L, Sadek M, Imirzalioglu C, Jul;1496(1):82-96.
Chakraborty T. Recent Emergence of Aztreonam-Avibactam Resistance
in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in 40. Tyers M, Wright GD. Drug combinations: a strategy to extend the life of
Germany. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0109021. antibiotics in the 21st century. Nat Rev Microbiol. 2019 Mar;17(3):141-
55.
22. Petropoulou D, Siopi M, Vourli S, Pournaras S. Activity of Sulbactam-
Durlobactam and Comparators Against a National Collection of 41. Klompas M. Monotherapy Is Adequate for Septic Shock Due to Gram-
Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece. Negative Organisms. Crit Care Med. 2017 Nov;45(11):1930-2.
Front Cell Infect Microbiol. 2022 Jan 20;11:814530.
42. De Bus L, Depuydt P, Steen J, Dhaese S, De Smet K, Tabah A, et al;
23. Segatore B, Piccirilli A, Cherubini S, Principe L, Alloggia G, Mezzatesta DIANA study group. Antimicrobial de-escalation in the critically ill
ML, et al. In Vitro Activity of Sulbactam-Durlobactam against patient and assessment of clinical cure: the DIANA study. Intensive Care
Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: Med. 2020 Jul;46(7):1404-17.
A Multicentre Report from Italy. Antibiotics (Basel). 2022 Aug
22;11(8):1136. 43. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French
C, et al. Surviving Sepsis Campaign: International Guidelines for
24. Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov
M, Álvarez-Fraga L, Alonso-García I, et al; GEMARA-SEIMC/REIPI 1;49(11):e1063-e1143.
Enterobacterales Study Group. Assessment of Activity and Resistance
Mechanisms to Cefepime in Combination with the Novel β-Lactamase 44. Sjövall F, Perner A, Hylander Møller M. Empirical mono- versus
Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a combination antibiotic therapy in adult intensive care patients with
Multicenter Collection of Carbapenemase-Producing Enterobacterales. severe sepsis - A systematic review with meta-analysis and trial
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0167621. sequential analysis. J Infect. 2017 Apr;74(4):331-44.
25. Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, et al. Effect of 45. Albasanz-Puig A, Gudiol C, Puerta-Alcalde P, Ayaz CM, Machado M,
Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure Herrera F, et al. Impact of the Inclusion of an Aminoglycoside to the
and Microbiological Eradication in Patients With Complicated Urinary Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream
Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. Infections in Hematological Neutropenic Patients: a Propensity-
JAMA. 2022 Oct 4;328(13):1304-14. Matched Cohort Study (AMINOLACTAM Study). Antimicrob Agents
Chemother. 2021 Jul 16;65(8):e0004521.
26. Giacobbe DR, Bassetti M. Innovative β-lactam/β-lactamase inhibitor
combinations for carbapenem-resistant Gram-negative bacteria. Future 46. Liljedahl Prytz K, Prag M, Fredlund H, Magnuson A, Sundqvist M,
Microbiol. 2022 Apr;17:393-6. Källman J. Antibiotic treatment with one single dose of gentamicin
at admittance in addition to a β-lactam antibiotic in the treatment of
27. Dowell JA, Marbury TC, Smith WB, Henkel T. Safety and community-acquired bloodstream infection with sepsis. PLoS One. 2020
Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Jul 30;15(7):e0236864.
Subjects with Various Degrees of Renal Impairment. Antimicrob Agents
Chemother. 2022 Sep 20;66(9):e0025322. 47. D Somogyi R, C Sheridan D. Recent Advances in Bedside Device-Based
Early Detection of Sepsis. J Intensive Care Med. 2022 Jul;37(7):849-56.
28. Zhanel GG, Pozdirca M, Golden AR, Lawrence CK, Zelenitsky S, Berry L,
et al. Sulopenem: An Intravenous and Oral Penem for the Treatment
of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs.
2022 Apr;82(5):533-57. Konflikt interesa: Nema
29. Eckburg PB, Muir L, Critchley IA, Walpole S, Kwak H, Phelan AM, et al. Primljeno: 26. 12. 2022.
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract
Infection. N Engl J Med. 2022 Apr 7;386(14):1327-38. Prihvaćeno: 15. 01. 2023.
Onlajn: 01. 03. 2023.
30. Sun Z, Su L, Cotroneo N, Critchley I, Pucci M, Jain A, et al. Evaluation
of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated
22 DOI: 10.5937/Galmed2305014S